The hypercoagulable state in thalassemia

Blood

Volumn 99, Issue 1, 2002, Pages 36-43

  Eldor, Amiram ^a   Rachmilewitz, Eliezer A ^b  

^a TEL AVIV UNIVERSITY   (Israel)

^b WOLFSON MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; DIPYRIDAMOLE;

ADULT; ALPHA THALASSEMIA; ANIMAL MODEL; BETA THALASSEMIA; DEEP VEIN THROMBOSIS; ENDOTHELIUM CELL; FIBRINOLYSIS; GRANULOCYTE; HEMOSTASIS; HUMAN; HYPERCOAGULABILITY; LEUKOCYTE ACTIVATION; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MONOCYTE; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; THALASSEMIA; THROMBOCYTE ACTIVATION; THROMBOEMBOLISM;

EID: 0036092892     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V99.1.36     Document Type: Review

References (99)

1. Survival and disease complications in thalassemia major
2. Thrombotic risk in thalassemic patients
3. A chronic hypercoagulable state and life-long platelet activation in beta thalassemia major
4. A chronic hypercoagulable state in patients with beta-thalassemia major is already present in childhood
5. The β-thalassemias
6. Thalassemia major (homozygous beta-thalassemia). A survey of 138 cases with emphasis on neurologic and muscular aspects
7. Thromboembolic events in beta thalassemia major: An Italian multicenter study
8. Cerebral thrombosis in beta-thalassemia/hemoglobin E disease
9. Venous thrombosis in hemoglobin H disease after splenectomy
10. A syndrome of hyper tension, convulsion, and cerebral haemorrhage irthalassemic patients after multiple blood-transfusions
11. Hypertension, convulsion, and cerebral haemorrhage in thalassemic patients after multiple blood transfusions
12. Convulsion after blood transfusion in four beta-thalassemia intermedia patients
13. Brain pathology in 6 fatal cases of post-transfusion hypertension, convulsion and cerebral hemorrhage syndrome
14. MR imaging of the brain: Findings in asymptomatic patients with thalassemia intermedia and sickle cell-thalassemia disease
15. Acute cerebrovascular insults in homozygous beta-thalassemia: A case report
16. Thromboembolic complications in beta thalassemia major
17. Pulmonary thromboembolism in thalassemia intermedia patients
18. Thromboembolic complications in an asplenic HbE-beta-thalassemia patient
19. Venous thromboembolism and hypercoagulability in splenectomized patients with thalassaemia intermedia
20. Pulmonary artery obstruction in thalassemia
21. Pulmonary microthromboemboli in thalassemic cases
22. Cardiopulmonary assessment in beta thalassemia major
23. Thalassemia: Lung function with reference to iron studies and reactive oxidant status
24. The effect of transfusion on lung capacity, diffusing capacity and material oxygen saturation in patients with β-thalassemia major
25. Right ventricular cardiac dysfunction in beta-thalassemia major
26. Pulmonary hypertension in patients with thalassemia major
27. Cardiac dysfunction in beta-thalassemic children
28. Abnormal platelet functions in beta thalassemia
29. Platelet function in beta-thalassemia major
30. Increased circulating platelet aggregates in thalassemia
31. Platelet survival in patients with beta-thalassemia
32. In vivo platelet activation in beta-thalassemia major reflected by increased platelet-thromboxane urinary metabolites
33. Thromboxane biosynthesis and platelet function in type II diabetes mellitus
34. Increased prostacyclin biosynthesis in patients with severe atherosclerosis and platelet activation
35. Platelet activation in unstable coronary disease
36. 2 formation
37. PADGEM/GMP-140 expression on platelet membranes from homozygous beta thalassemic patients
38. In-vivo platelet activation correlates with red cell anionic phospholipid exposure in patients with beta-thalassemia major
39. Differentiation of platelets from red cell fragments using laser technology: Comparison between splenectomized and nonsplenectomized thalassemic patients
40. Increase in spontaneous platelet aggregation in beta-thalassemia/hemoglobin E disease: A consequence of splenectomy
41. Detection of PF3 availability in whole blood from volunteers and beta-thalassemia/HbE patients: A promising method for prediction of thrombotic tendency
42. Morphological assessment of platelet activation in thalassemia
43. Alterations in vascular endothelial cell-related plasma proteins in thalassemic patients and their correlation with clinical symptoms
44. Possible evidence of endothelial cell activation and disturbance in thalassemia: An in vitro study
45. Adherence of phosphatidylserine-exposing erythrocytes to endothelial matrix thrombospondin
46. Enhanced adherence of beta-thalassemic erythrocytes to endothelial cells
47. Erythrocyte-endothelial cell adherence in sickle cell disorders
48. Interaction of sickle erythrocytes with endothelial cells in the presence of endothelial cell conditioned medium induces oxidant stress leading to transendothelial migration of monocytes
49. Increased serum levels of macrophage colony-stimulating factor (M-CSF) in alpha- and beta-thalassemia syndromes: Correlation with anaemia and monocyte activation
50. Activated monocytes in sickle cell disease: Potential role in the activation of vascular endothelium and vaso-occlusion
51. Elevated polymorphonuclear phagocytic function in thalassemia patients by chemiluminescence
52. Effect of the Leukostop filter on pulmonary function following blood transfusion in patients with thalassemia major
53. Significance of blood coagulation and platelet profiles in relation to pulmonary thrombosis in beta-thalassemia/Hb E
54. Protein C and protein S deficiency in thalassemic patients
55. Protein C antithrombin III in poly-transfused thalassemic patients
56. Low plasma heparin cofactor II levels in thalassemia syndromes are corrected by chronic blood transfusion
57. Studies on sickled erythrocytes provide evidence that the asymmetric distribution of phosphatidylserine in the red cell membrane is maintained by both ATP-dependent translocation and interaction with membrane skeletal proteins
58. Measurement of membrane phospholipid asymmetry in normal and sickle cell erythrocytes by means of annexin V binding
59. Thrombosis in heritable hemolytic disorders
60. Phosphatidylserine in the outer leaflet of red blood cells from beta-thalassemia patients may explain the chronic hypercoagulable state and thrombotic episodes
61. Comparison of the procoagulant activity of red blood cells from patients with homozygous sickle cell disease and b-thalassemia
62. Detection of altered membrane phospholipid asymmetry in subpopulations of human red blood cells using fluorescently labeled annexin V
63. Transbilayer movement of phospholipids in red cell and platelet membranes
64. Mechanism and function of changes in membrane phospholipid asymmetry in platelets and erythrocytes
65. Exposure of phosphatidylserine in the outer leaflet of human red blood cells. Relationship to cell density, cell age and clearance by mononuclear cells
66. Membrane phospholipid asymmetry in human thalassemia
67. Hemoglobinopathies and red cell membrane function
68. Metabolic indicators of oxidative stress correlate with haemichrome attachment to membrane, band 3 aggregation and erythrophagocytosis in beta-thalassemia intermedia
69. Role of hemichrome binding to erythrocyte membrane in the generation of band-3 alterations in beta-thafassemia intermedia erythrocytes
70. Enhanced aggregability of red blood cells of beta-thalassemia major patients
71. Targeted inactivation of murine band 3 (AE1) gene produces a hypercoagulable state causing wide-spread thrombosis in vivo
72. Thrombosis and secondary hemochromatosis play major roles in the pathogenesis of jaundiced and spherocytic mice, murine models for hereditary spherocytosis
73. Reduced incidence of thrombosis in mice with hereditary spherocytosis following neonatal treatment with normal hematopoietic cells
74. 2 agonist U46619
75. Enhanced thrombin generation in children with sickle cell disease
76. Low-intensity oral anticoagulation in sickle-cell disease reverses the prethrombotic state: Promises for treatment?
77. Sickle cell disease and stroke
78. Ischemic stroke in sickle cell disease: A review
79. Stroke prevention in sickle cell disease
80. Multicenter prospective study of children with sickle cell disease: Radiographic and psychometric correlation
81. Silent cerebral infarcts in sickle cell anemia: A risk factor analysis
82. Platelets, coagulation, and fibrinolysis in sickle cell disease: Their possible role in vascular occlusion
83. Case report: Sickle cell trait and recurrent deep venous thrombosis
84. Portal vein thrombosis in a child with homozygous sickle-cell disease
85. Pulmonary embolism developing in patients with sickle cell disease on hypertransfusion and IV deferoxamine chelation therapy
86. Venous thromboembolism, factor V Leiden, and methylenetetrahydrofolate reductase in a sickle cell anemia patient
87. Blood protein C and S sickle cell disease
88. Plasma protein C levels in children with sickle cell disease
89. Thrombogenesis in sickle cell disease
90. Circulating activated endothelial cells in sickle cell anemia
91. Tissue factor expression by endothelial cells in sickle cell anemia
92. Stroke prevention trial in sickle cell anemia
93. Risk of recurrent stroke in patients with sickle cell disease treated with erythrocyte transfusions
94. Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography
95. Knockout-transgenic mouse model of sickle cell disease
96. Transgenic knockout mice with exclusively human sickle hemoglobin and sickle cell disease
97. Paroxysmal nocturnal hemoglobinuria: The disease and a hypothesis for a new treatment
98. Portal vein thrombosis in paroxysmal nocturnal hemoglobinuria
99. Thrombo-embolic disease after splenectomy for hereditary stomatocytosis